Affimed N.V. (AFMD)
| Market Cap | 322.57M |
| Revenue (ttm) | 36.11M |
| Net Income (ttm) | -80.27M |
| Shares Out | 149.34M |
| EPS (ttm) | -0.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,044,668 |
| Open | 2.17 |
| Previous Close | 2.14 |
| Day's Range | 2.11 - 2.24 |
| 52-Week Range | 1.93 - 7.35 |
| Beta | 2.30 |
| Analysts | Buy |
| Price Target | 10.69 (+394.9%) |
| Earnings Date | Oct 27, 2022 |
About AFMD
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa ... [Read more...]
Financial Performance
In 2021, Affimed's revenue was 40.37 million, an increase of 42.33% compared to the previous year's 28.36 million. Losses were -57.52 million, 39.1% more than in 2020.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for AFMD stock is "Buy." The 12-month stock price forecast is 10.69, which is an increase of 394.91% from the latest price.
News
Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (E...
HEIDELBERG, Germany, Sept. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, toda...
Affimed to Present at Upcoming Investor Conferences
HEIDELBERG, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks
This billionaire-guided hedge fund went bargain-shopping in the second quarter.
Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 22.22% and 4.22%, respectively, for the quarter ended June 2022.
Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress
HEIDELBERG, Germany, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022
HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
7 Undervalued Biotech Stocks to Buy Before They Boom
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy. The post 7 Undervalued Biotech Stocks to Buy Before They Boom appeared ...
Affimed Establishes Scientific Advisory Board
HEIDELBERG, Germany, June 30, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology...
HEIDELBERG, Germany, June 10, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 11.11% and 9.57%, respectively, for the quarter ended March 2022.
Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress
HEIDELBERG, Germany, June 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
Affimed Highlights Trial Designs of Three AFM24 Ongoing Clinical Studies at the Annual Meeting of the American Societ...
HEIDELBERG, Germany, May 26, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
Affimed to Present at the 2022 Jefferies Healthcare Conference
HEIDELBERG, Germany, May 26, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Affimed N.V. (AFMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Affimed Announces Annual General Meeting of Shareholders
HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
Affimed to Report First Quarter 2022 Financial Results & Corporate Update on June 1, 2022
HEIDELBERG, Germany, May 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
Affimed Presents Data on Innate Cell Engagers AFM24 and AFM28 at 19th Meeting of the Society for Natural Immunity
HEIDELBERG, Germany, May 16, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
Affimed to Present Preclinical Data Demonstrating Cytotoxic Activity of its Novel Innate Cell Engager AFM28 at the An...
HEIDELBERG, Germany, May 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
3 Small-Caps That Might Be Acquisition Candidates
Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.
Affimed Provides Update on ASCO AFM13-104 Oral Presentation
HEIDELBERG, Germany, May 06, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate a...
CORRECTING and REPLACING -- Affimed N.V.
In a press release issued earlier today by Affimed N.V. (Nasdaq: AFMD), please note that the headline named an incorrect organization. It should have mentioned the annual meeting of the American Society...
Affimed Announces Clinical Update and Trial in Progress Posters at the Annual Meeting of the American Association for...
HEIDELBERG, Germany, April 27, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, toda...
Affimed Announces Closing of Public Offering of Common Shares and Full Exercise of Underwriters' Option to Purchase A...
HEIDELBERG, Germany, April 18, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical stage immuno-oncology company committed to giving patients back their innate ...
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares
HEIDELBERG, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...